Showing 6541-6550 of 7313 results for "".
- Use of Personal Care Products During Pregnancy Linked to Adverse Effects in Newbornshttps://practicaldermatology.com/news/use-of-personal-care-products-during-pregnancy-linked-to-adverse-effects-in-newborns/2458575/Personal care products used during pregnancy may be linked to adverse reproductive effects in newborns, report researchers from SUNY Downstate Medical Center’s School of Public Health. The long-term consequences of this are not clear and the findings must be reproduced in larg
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- Teledermatology Improves Access to Carehttps://practicaldermatology.com/news/teledermatology-improves-access-to-care/2458577/Teledermatology improves access to care, a new study suggests. In the study of primary care practices in a large California Medicaid managed care plan, those practices that engaged in teledermatology had a 64 percent increase in the fraction of patients vis
- Lilly's Taltz Now Available for Psoriasishttps://practicaldermatology.com/news/lillys-taltz-now-available-for-psoriasis/2458581/Eli Lilly and Company's Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programs to help ensu
- Study IDs Rosacea-Alzheimers Linkhttps://practicaldermatology.com/news/study-ids-rosacea-alzheimers-link/2458584/Rosacea may be linked to an increased risk of dementia—in particular Alzheimer’s disease, new research suggests. This risk was highest in older patients and in patients where rosacea was diagnosed by a hospital dermatologist. The new findings are published in the </
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's
- Tight Ponytails, Braids Linked to Traction Alopeciahttps://practicaldermatology.com/news/tight-ponytails-braids-linked-to-traction-alopecia/2458588/New research confirms a “strong association” between scalp-pulling hairstyles such as tight ponytails, braids, knots and buns and the development of traction alopecia. The review study is published ahead of print in the
- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red